We received a great pressrelease from Roche. Risdiplam is a milestone ahead. Basel, 26 February 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of EvrysdiTM (risdiplam) for the treatment of 5q spinal muscular atrophy… Fortsätt läsa Evrysdi (Risdiplam) receives positive CHMP opinion for spinal muscular atrophy (SMA) treatment . The first only oral treatment at home for patients with spinal muscular atrophy
Kategori: Genetisk sjukdom
Alt om spinal muskelatrofi og genetisk sykdom
New results from Evrysdi (risdiplam) study
in infants with spinal muscular atrophy (SMA) type I Roche announces further new results on the Firefish study. These were also published in the New England Journal of Medicine In the low- and high-dose cohorts, no infant lost the ability to swallow over 12 months, and 86% (18/21) were able to feed orally, either exclusively… Fortsätt läsa New results from Evrysdi (risdiplam) study